Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:15:48.712Z.
Calculation as of: 2026-10-06T14:15:48.712Z.
Quote observation: 2026-10-06T14:15:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Anteris Technologies Global Corp.
Market Cap
$708.82M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$714.62M
Price/FCF Ratio
2.18
TTM Avg
4.81
3Y Avg
5.21
5Y Avg
6.10
Market Cap
$710.80M
Price/FCF Ratio
N/A
TTM Avg
4.42
3Y Avg
4.41
5Y Avg
4.41
Market Cap
$716.99M
Price/FCF Ratio
N/A
TTM Avg
1186.25
3Y Avg
1180.14
5Y Avg
1180.14
Market Cap
$761.30M
Price/FCF Ratio
N/A
TTM Avg
30.96
3Y Avg
280.40
5Y Avg
522.37
Market Cap
$756.25M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $708.82M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $714.62M | 2.18 | 4.81 | 5.21 | 6.10 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $710.80M | N/A | 4.42 | 4.41 | 4.41 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $716.99M | N/A | 1186.25 | 1180.14 | 1180.14 |
| Candel Therapeutics, Inc. (CADL)vs › | $742.96M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $749.29M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $678.37M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $761.30M | N/A | 30.96 | 280.40 | 522.37 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $756.25M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $667.66M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
